Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
NIAID-supported research sheds light on why healthy people of the same age respond differently to vaccines.
A single vaccine dose delivered to nose aims to protect children and adults against COVID.
Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.
Cancer patients undergoing treatment and those with suppressed immune systems eye the future—and the COVID pandemic’s wane—warily.
Studies evaluate the impact of COVID-19 infection, treatments and vaccination in this uniquely vulnerable population.
The findings suggest boosters not only lengthen immunity but help broaden and strengthen the immune response.
The findings could have implications for vaccines against other rapidly evolving pathogens, such as influenza virus or SARS-CoV-2.
Evidence is growing that contracting SARS-CoV-2 is generally as effective as vaccination at preventing COVID-19.
People who received the Moderna COVID-19 vaccine had strong immune memory of SARS-CoV-2 six months after vaccination.
What protects most children from becoming seriously ill? And why does that protection sometimes fail?
About half of people hospitalized with COVID-19 had antibodies that could mistakenly attack the body’s own proteins and tissues.
Scientific evidence appears to show that vaccine-induced immunity is stronger than what the body generates after natural infection.
Bamlanivimab and etesevimab may be given to people with mild to moderate COVID-19 who are at high risk for progression to severe disease.
More than 95% of people who recovered from COVID-19 had durable immune system memory up to eight months after infection.
Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.